Blueprint Medicines Corp. has disclosed PROTAC compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful for the treatment of cancer.
Generative AI drug discovery company Vantai Inc. could bring in more than $1 billion in a new collaboration with Halda Therapeutics Inc. Vantai already has collaborations with other companies, including Bristol Myers Squibb Co. (BMS), Janssen Pharmaceutica and Blueprint Medicines Corp.
The BioWorld Drug Developers Index (BDDI) rebounded in the second quarter, ending the first half (H1) of 2025 up 1.23% after being down 7.36% at the end of March and 5.52% at April’s close. The BDDI continued to track just below the Dow Jones Industrial Average, which gained 3.64% in H1, and outperformed the Nasdaq Biotechnology Index, which ended June down 1.92%.
Blueprint Medicines Corp. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a cyclin dependent kinase 2 (CDK2)-targeting moiety through a linker reported to be useful for the treatment of cancer.
At the recent AAAAI/WAO meeting, Blueprint Medicines Corp. presented the in vitro and in vivo characterization of BLU-808, a selective inhibitor of wild-type KIT, a transmembrane receptor tyrosine kinase involved in mast cell activation, proliferation and chemotaxis.
Mast/stem cell growth factor receptor KIT is a receptor tyrosine kinase that plays a key role in mast cell differentiation, proliferation, survival and activation.
